G1 Therapeutics (GTHX) is a clinical stage pharmaceutical company based in Durham, NC. It is a company with several pipeline products in oncology focusing on modulating the activity of CDK4 and CDK6 cell cycle related enzymes in cancer patients.
It recently IPO in May 17, 2017 at $15/share and raise $105M from the IPO. The IPO was led by JPM and Cowen & Co. The capital from the IPO will be used to develop the 3 pipeline products, which $45M will be allocated to develop its frontrunner, trilaciclib in various cancer indications. Its current price is around $16-17/share.
Its current 12-months target prices are:
JP Morgan: $23.00 +35.3% (6/12/2017),
Needham & Co.: $34.00 +100% (6/12/2017) and
WedBush: $31.00 +82.4% (6/11/2017).
We have conducted further research analyses on the preclinical data – next page